Fidson has been saving lives, now it’s offering you ownership
Fidson Healthcare has been saving Nigerian lives for almost 30 years. That’s not small. In a country where “healthcare” sometimes feels like a prayer point, any company that has stayed consistent in medicine for decades deserves attention.
Now, Fidson is giving its existing shareholders a chance to own more of the business at ₦35 per share. So the big question is simple: should you take this opportunity seriously, or should you ignore it like another random stock notice?
Let’s gist.
Tomi and Tobi saw the same notice, but only one understood it
Tomi and Tobi both saw the Fidson notice. Tobi shrugged and said, “I’ll look at it later.” Tomi asked, “Wait… what does this really mean?”That small difference is how wealth changes hands quietly. Because years later, one person owns more of a growing healthcare company. The other one only remembers the headline and starts saying, “Ah! I wanted to buy that thing then…”
Many financial regrets start with “later.”
What Fidson is doing is not a public offer
First, let’s clear confusion.
Fidson Healthcare Plc is issuing 600 million new shares at ₦35. But this one is not for everybody on the street. It’s not a “come and buy” public offer. It is a rights issue. Meaning: only existing shareholders have the right to buy more shares.
The rule is straightforward:
For every 4 shares you already own, you can buy 1 new share.
So if you already have Fidson shares in your portfolio, this is Fidson telling you:
“Oga/Madam shareholder, if you want to increase your ownership at this fixed price, here’s your chance.”
That’s what a rights issue really is: an invitation for existing shareholders to increase their ownership. Not a raffle draw. Not a rumour. Not vibes. Ownership.
Fidson is not a random ticker, it’s a real manufacturer
One reason people ignore Nigerian stocks is because they think it’s all paper games. But Fidson is not a random ticker.
Fidson is a major Nigerian pharmaceutical manufacturer:
- Incorporated in 1995
- Manufacturing since 2002
- Listed on the stock market in 2008
- WHO-compliant facility on about 40 acres in Sango Ota
Now, pause.
Do you know how serious it is to run a pharma manufacturing business for decades in Nigeria? Between FX wahala, import stress, power cost, regulation, and raw material issues… many people can’t even keep a small POS business stable for 2 years. So a company that has built this kind of foundation is not joking. And the timing matters.
Healthcare demand is rising.
Local manufacturing matters more.
Imports are risky.
FX is unstable.
So this capital raise is not about “we are dying, please save us.”
No.
This is about strengthening capacity, scaling production, and positioning for the future of Nigerian healthcare. In simple words, they are building bigger.
Follow performance, not noise
Before you add capital to any company, you must ask one question: Is this business growing or gasping?
Fidson’s 2024 numbers show growth:
- Revenue grew 59% to ₦84.2bn
- Gross profit grew 67% to ₦35.1bn
- Operating profit grew 64% to ₦13.1bn
- Total assets reached ₦73.5bn (+19%)
This is not the performance of a struggling company. This is a business expanding steadily. So when you see a rights issue like this, it can be a sign that the company is saying:
“We have something bigger to do. We want existing owners to have first chance to grow with us.”
This is not just a stock, it’s an industrial healthcare platform
Some businesses are just “buy and sell.” But Fidson is deeper than that.
This company has:
- 350+ NAFDAC-registered products
- 10 production lines
- Nigeria’s largest pharma facility
- Manufacturing partnerships with GSK, Bayer, and Serum Institute
These are not small partners. When a company can produce at this level, it can:
Serve more people → earn more revenue → defend market share → grow long-term value.
And Fidson didn’t start today. They have pioneered major milestones like:
- Local ARV production
- Ampoule injections in Nigeria
- WHO-compliant facilities
- Exports across Africa & the Middle East
This type of leverage takes decades to build. That’s why Fidson is one of the few Nigerian manufacturers with real scale, real partners, and real demand behind it.
So should you take the rights issue seriously?
If you’re the kind of investor who likes quick “enter today, exit tomorrow,” this may not excite you. But if you are a patient, long-term investor who likes productive businesses—especially in an industry like healthcare that Nigeria cannot outgrow—then yes…
Taking your rights seriously is a mature move. Not because it’s guaranteed money. Nothing is. But because it’s ownership in a company that is building capacity in a sector that Nigerians will always need.
People will always fall sick.
Babies will always be born.
Hospitals will always buy medicine.
Africa will always need healthcare.
That demand is not going anywhere.
How to plug in step by step
To participate, Fidson has made it simple:
- Open https://myrightsdata.meristemregistrars.ng
- Search using Name, RAN, Email, Phone, or CHN
- Verify your shareholder details and entitlement
- Follow the portal instructions for participation and payment
- Save proof of submission before 30 Jan 2026
No story. Just follow process.
The real lesson is bigger than Fidson
This is not only about Fidson. It’s about how wealth rewards people who pay attention.
Tobi said, “later.”
Tomi asked, “what does this mean?”
And that is the difference between people who consume headlines and people who build portfolios.
Remember, we don’t grow by learning alone.
We grow by doing.
Grab the gist?
